The fibroblast growth factor receptor (FGFR) pathway is very important in bladder cancer. Dr Laura Mertens (VU Amsterdam Medical Center, the Netherlands) shared her data analysing activating FGFR3 mutations vs FGFR3 protein overexpression in bladder tumours and their relation to clinic-pathological parameters and prognosis in a multicentre, multi-laboratory setting. She concluded that FGFR3 mutation has favourable prognostic impact regardless of FGFR3 protein expression level.
FGFR3 activating mutations are known to be associated with favourable prognosis in bladder cancer , yet little is known about whether immunohistochemical detection of overexpression of FGFR3 is a relevant prognostic tool. Because the FGFR3 receptor is an actionable target and there are drugs in the pipeline, Dr Mertens took 1,000 cN0M0 (chemo-naïve) bladder cancer patients who underwent radical cystectomy (in 9 hospitals) and concomitantly screened them ...
please login to read the entire article:
You need to register to read the entire article, please do so now.
« Focus on treatment of erectile dysfunction and Peyronie’s disease Next Article
When to Use Imaging and Imaging-guided Therapies »
Table of Contents: EAU 2019
Renal Transplantation and Renal Cell Carcinoma
Lower Urinary Tract Symptoms
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.